| Neogene Therapeutics–TPG: investment, 202009 financing round Series A totalling $110m incl existing + co-investor TPG |
2020-09-14 |
| Neogene Therapeutics–Two River: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Two River |
2020-09-14 |
| Neogene Therapeutics–Vida Ventures: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Vida Ventures |
2020-09-14 |
| Immunomedics–Gilead: investment, 202009–202010 acquisition $21m cash tender offer at $88/share |
2020-09-13 |
| Neurogeneus–SEVERAL: investment, 202009 seed financing round £12m with Advent LS + DDF + F-Prime Capital + JJDC + LifeArc |
2020-09-11 |
| Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation |
2020-09-09 |
| United States (govt)–Intravacc: EV D68 vaccine, 202009– co-development contract up to $9.4m for prophylactic enterovirus D68 vaccine with NIAID |
2020-09-08 |
| Imcyse–MC Services: public relations, 202009 service existent by MC Services |
2020-09-07 |
| Amarna Therapeutics–LifeSpring: public relations, 202009 service existent by LifeSpring Communications |
2020-09-03 |
| Biocartis–LifeArc: molecular diagnostics, 202009– collab expansion €na developm of MDx tests for infectious + immune diseases for Idylla platform |
2020-09-01 |
| Neogene Therapeutics–W2O Group: public relations, 202009 service existent W2O Group is media contact |
2020-09-01 |
| Univercells–Adjuvant Capital: investment, 202009 financing round Series C first closing totalling €50m incl co-lead investor Adjuvant Capital |
2020-09-01 |
| Univercells–Belgium (govt): investment, 202009 financing round Series C first closing totalling €50m incl co-lead investor SFPI |
2020-09-01 |
| Univercells–SEVERAL: investment, 202009 financing round Series C first closing €50m led by Adjuvant Capital + SFPI + SRIW |
2020-09-01 |
| Univercells–Wallonia (govt): investment, 202009 financing round Series C first closing totalling €50m incl co-lead investor SRIW |
2020-09-01 |
| Semalytix–btov Partners: investment, 202008 financing round Series A totalling €4.3m incl co-lead investor btov |
2020-08-31 |
| Semalytix–Fly Ventures: investment, 202008 financing round Series A totalling €4.3m incl existing sedd + co-lead investor Fly Ventures |
2020-08-31 |
| Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures |
2020-08-31 |
| Intact Vascular–Philips: investment, 202008– acquisition $275m upfront + $85m at closing of transaction |
2020-08-27 |
| NewAmsterdam Pharma–Forbion: investment, 202008 seed financing round totalling €20m from Forbion + founders |
2020-08-25 |
| NewAmsterdam Pharma–McDougall Communications: public relations, 202008 service existent by McDougall |
2020-08-25 |
| NewAmsterdam Pharma–SEVERAL: investment, 202008 seed financing round €20m from Forbion + founders |
2020-08-25 |
| Galapagos–Scipher Medicine: AI-based drug discovery, 202008– collab IBD drug target valuation with excl option rights for developm for Galapagos |
2020-08-12 |
| Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV |
2020-08-11 |
| Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF |
2020-08-11 |
| CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market |
2020-08-10 |
| Dyne Therapeutics–Forbion: investment, 202008 financing round totalling $115m incl existing + co-investor Forbion |
2020-08-10 |
| Dyne Therapeutics–SEVERAL: investment, 202008 financing round $115m co-led by new investors Vida Ventures + Surveyor Capital |
2020-08-10 |
| Bruker–Univ Utrecht: mass spectromtery, 202008– collab developm of methods using crosslinkg MS for proteomics with Heck lab |
2020-08-07 |
| VectorY–Forbion: investment, 202008 founding + seed investor Forbion |
2020-08-01 |
| DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital |
2020-07-29 |
| Vico Therapeutics–LifeSpring: public relations, 202007 service existent by LifeSpring Communications |
2020-07-29 |
| ExeVir Bio–Belgium (govt): investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor SFPI-FPIM |
2020-07-28 |
| ExeVir Bio–Fund+: investment, 202007 financing round Series A 1st closing totalling €23m incl lead investor Fund+ |
2020-07-28 |
| ExeVir Bio–Optimum Strategic Communications: public relations, 202007 service existent by Optimum |
2020-07-28 |
| ExeVir Bio–OTHER: investment, 202007 financing round Series A 1st closing totalling €23m incl several Belgian family offices |
2020-07-28 |
| ExeVir Bio–SEVERAL: investment, 202007 financing round Series A 1st closing of €23m led by Fund+ |
2020-07-28 |
| ExeVir Bio–UCB: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor UCB Ventures |
2020-07-28 |
| ExeVir Bio–V-Bio Ventures: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor V-Bio Ventures |
2020-07-28 |
| ExeVir Bio–VIB: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor VIB |
2020-07-28 |
| iTeos Therapeutics–SEVERAL: investment, 202007 IPO $201.1m+$30.2m with 10.59m+1.59m shares at $19/share at Nasdaq |
2020-07-23 |
| CureVac–GSK: investment, 202007 financing round Series B totalling €560m incl €150m from Glaxo Group Ltd |
2020-07-17 |
| CureVac–Qatar (govt): investment, 202007 financing round Series B totalling €560m incl €60m from Qatar Investment Authority |
2020-07-17 |
| CureVac–SEVERAL: investment, 202007 financing round Series B €560m incl €300m from KfW + €150m from GSK + €60m from QIA |
2020-07-17 |
| Nkarta–SEVERAL: investment, 202007 IPO $252m+37.8m with 14m+2.1m shares common stock at $18/share at Nasdaq Global Select Market |
2020-07-10 |
| Belgian Growth Fund–Belgium (govt): investment, 202007 final closing totalling €34m incl existing investor SFPI bringing total to €312m |
2020-07-09 |
| Belgian Growth Fund–Flanders (govt): investment, 202007 final closing totalling €34m incl existing investor PMV bringing total to €312m |
2020-07-09 |
| Belgian Growth Fund–SEVERAL: investment, 202007 final closing with additional €34m bringing total fund size to €312m |
2020-07-09 |
| Belgian Growth Fund–UZ Brussel: investment, 202007 final closing totalling €34m incl new investor UZ Brussel Pension Fund bringing total to €312m |
2020-07-09 |
| Belgian Growth Fund–water-link: investment, 202007 final closing totalling €34m incl new investor water-link Pension Fund bringing total to €312m |
2020-07-09 |
| IntegraGen–OncoDNA: investment, 202007–202011 acquisition public offer at €2.2/share valuing IntegraGen at €14.5m |
2020-07-08 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| VarmX–Instinctif Partners: public relations, 202007 service existent by Instinctif |
2020-07-08 |
| VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital |
2020-07-08 |
| CVRx–Gilde Investment: investment, 202007 equity investment totalling $50m incl existing + co-investor Gilde Healthcare |
2020-07-07 |
| CVRx–SEVERAL: investment, 202007 raises $50m equity investment to close latest financing round co-led by SHLP + Vensana Capital |
2020-07-07 |
| Molecular Partners–SEVERAL: investment, 202007 private placement CHF80.2m from new + existing European + US institutional investors |
2020-07-06 |
| Citryll–BioGeneration Ventures: investment, 202007 financing round Series A totalling €18.5m incl new + co-lead investor BioGeneration Ventures |
2020-07-02 |
| Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund |
2020-07-02 |
| Citryll–Netherlands (govt): credit, 202007 Innovation Credit from RVO |
2020-07-02 |
| Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures |
2020-07-02 |
| Forbion–Belgian Growth Fund: investment, 202007 first close €185m of Forbion GO Fund incl €20m from Belgian Growth Fund |
2020-07-01 |
| Cergentis–Novalis Biotech Incubation: investment, 202006 investment by Novalis Biotech Incubation fund |
2020-06-29 |
| CSL–Uniqure: gene therapy, 202006– license excl ww $450m upfront + $1.6b milestones + royalties for hemophilia B gene therapy AMT-061 |
2020-06-24 |
| Scenic Biotech–Netherlands (govt): credit, 202006– Innovation Credit €3.1m from RVO to advance QPCTL inhibitors |
2020-06-23 |
| ArcherDx–Invitae: investment, 202006– acquisition merger up to $1.4b with $325m cash + 30m shares + up to addit 27m shares milestone-dependent |
2020-06-22 |
| BlueBee–Illumina: investment, 202006 acquisition €na of BlueBee by Illumina |
2020-06-17 |
| China Grand Pharma–eTheRNA: mRNA technology, 202006– collab outline terms of potential strategic partnership R+D + production + sales in Greater China |
2020-06-16 |
| eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity |
2020-06-16 |
| eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF |
2020-06-16 |
| eTheRNA–China Grand Pharma: investment, 202006 financing round Series B totalling €34m incl new investor Grand Decade |
2020-06-16 |
| eTheRNA–Flanders (govt): investment, 202006 financing round Series B totalling €34m incl existing investor PMV |
2020-06-16 |
| eTheRNA–Fund+: investment, 202006 financing round Series B totalling €34m incl existing investor Fund+ |
2020-06-16 |
| eTheRNA–Life Sciences Partners: investment, 202006 financing round Series B totalling €34m incl existing investor LSP |
2020-06-16 |
| eTheRNA–Novalis LifeSciences: investment, 202006 financing round Series B totalling €34m incl new investor Novalis LifeSciences LLC |
2020-06-16 |
| eTheRNA–Omega Funds: investment, 202006 financing round Series B totalling €34m incl existing investor Omega Funds |
2020-06-16 |
| eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors |
2020-06-16 |
| eTheRNA–Yijing Capital: investment, 202006 financing round Series B totalling €34m incl new investor Yijing Capital |
2020-06-16 |
| Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital |
2020-06-16 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| The Clinical Company–Excelya: investment, 202007 acquisition |
2020-06-07 |
| Hyloris Pharmaceuticals–SEVERAL: investment, 202006 IPO $65.2m at $12/share at Euronext Brussels |
2020-06-03 |
| Prilenia–Forbion: investment, 202006 financing round Series A totalling $62.5m incl new + lead investor Forbion |
2020-06-03 |
| Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 |
2020-06-03 |
| Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif |
2020-06-03 |
| Prilenia–Morningside: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Morningside Venture Investments |
2020-06-03 |
| Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management |
2020-06-03 |
| Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion |
2020-06-03 |
| Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners |
2020-06-03 |
| Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital |
2020-05-27 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
